Investigating and critically appraising the expression and potential role of androgen receptor in breast carcinoma

Hormone Molecular Biology and Clinical Investigation

Volumn 7, Issue 1, 2011, Pages 273-278

  Peter, Mark B ^a,b   Rajan, Sree Sundara ^a,b   Maraqa, Loaie ^a,b   Horgan, Kieran ^a   Speirs, Valerie ^a,d   Shaaban, Abeer M ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c ST JAMES S INSTITUTE OF ONCOLOGY   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

androgen receptor; breast cancer; prognosis

Indexed keywords

ANDROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE RISK; RISK REDUCTION; TISSUE MICROARRAY;

EID: 84973530358     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/HMBCI.2011.116     Document Type: Article

References (38)

1. Allegra JC., Lippmann ME., Thompson EB., Simon R., Barlock A., Green L., Huff KK., Do HM., Aitken SC. Distribution., frequency, and quantitative analysis of estrogen., progesterone, androgen., and glucocorticoid receptors in human breast cancer. Cancer Res 1979;39:1447-54.
2. Nicolas Diaz-Chico B., German Rodriguez F., Gonzalez A., Ramirez R., Bilbao C., Cabrera De Leon A., Aguirre Jaimie A., Chirino R., Navarro D., Diaz-Chico JC. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007;105:1-15.
3. Secreto G., Toniolo P., Berrino F., Recchione C., Di Pietro S., Fariselli G., Decarli A. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res 1984;44: 5902-5.
4. Ingle JN., Twito DI., Schaid DJ., Cullinan SA., Krook JE., Mail-liard JA., Tschetter LK., Long HJ., Gerstner JG., Windschitl HE. Combination hormonal therapy with tamoxifen plus fluoxy-mesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991;67:886-91.
5. Burstein HJ., Prestrud AA., Seidenfeld J., Anderson H., Buchholz TA., Davidson NE., Gelmon KE., Giordano SH., Hudis CA., Malin J., Mamounas EP., Rowden D., Solky AJ., Sowers MR., Stearns V., Winer EP., Somerfield MR., Griggs JJ. American society of clinical oncology. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784-96.
6. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax SF., Wey-bora W., Ratschek M., Tavassoli FA., Denk H. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003;98: 703-11.
7. Zhuang YH., Saaristo R., Ylikomi T. An in vitro long-term culture model for normal human mammary gland: expression and regulation of steroid receptors. Cell Tissue Res 2003;311: 217-26.
8. Agoff SN., Swanson PE., Linden H., Hawes SE., Lawton TJ. Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical., clinical, and prognostic associations. Am J Clin Pathol 2003;120:725-731.
9. Riva C., Dainese E., Caprara G., Rocca PC., Massarelli G., Tot T., Capella C., Eusebi V. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma Virchows Arch 2005;447: 695-700.
10. Kuenen-Boumeester V., Van Der Kwast TH., Claassen CC., Look MP., Liem GS., Klijn JG., Henzen-Logmans SC. The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters. Eur J Cancer 1996;32A: 1560-5.
11. Hall RE., Aspinall JO., Horsfall DJ., Birrell SN., Bentel JM., Sutherland RL., Tilley WD. Expression of the androgen receptor and an androgen-responsive protein., apolipoprotein D., in human breast cancer. Br J Cancer 1996;74:1175-80.
12. Agrawal AK., Jeleñ M., Grzebieniak Z., Zukrowski P., Rudnicki J., Nienartowicz E. Androgen receptors as a prognostic and predictive factor in breast cancer. Folia Histochem Cytobiol 2008;46:269-76.
13. Schippinger W., Regitnig P., Dandachi N., Wernecke KD., Bauernhofer T., Samonigg H., Moinfar F. Evaluation of the prognostic significance of androgen receptor expression in meta-static breast cancer. Virchows Arch 2006;449:24-30.
14. Park S., Koo J., Park HS., Kim JH., Choi SY., Lee JH., Park BW., Lee KS. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21:488-92.
15. Cho LC., Hsu YH. Expression of androgen., estrogen and progesterone receptors in mucinous carcinoma of the breast. Kao-hsiung J Med Sci 2008;24:227-32.
16. Birrell SN., Bentel JM., Hickey TE., Ricciardelli C., Weger MA., Horsfall DJ., Tilley WD. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 995;52:459-67.
17. Iobagiu C., Lambert C., Normand M., Genin C. Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res Treat 2006;95:153-9.
18. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol 2008;4:15-21.
19. Soiland H., Korner H., Skaland I., Janssen EA., Gudlaugsson E., Varhaug JE., Baak JP., Soreide JA. Prognostic relevance of androgen receptor detection in operable breast cancer. J Surg Oncol 2008;98:551-8.
20. Moe RE., Anderson BO. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 2007;95:437-9.
21. Maraqa L., Cummings M., Peter MB., Shaaban AM., Horgan K., Hanby AM., Speirs V. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen. Clin Cancer Res 2008;14:405-11.
22. Hamilton-Burke W., Coleman L., Cummings M., Green CA., Hol-liday DL., Horgan K., Maraqa L., Peter MB., Pollock S., Shaaban AM., Smith L., Speirs V. Phosphorylation of estrogen receptor β at serine 105 is associated with good prognosis in breast cancer. Am J Pathol 2010;177:1079-86.
23. Shaaban AM., Green AR., Karthik S., Alizadeh Y., Hughes TA., Harkins L., Ellis IO., Robertson JF., Paish EC., Saunders PT., Groome NP., Speirs V. Nuclear and cytoplasmic expression of ERΒ1, ERΒ2, and ERΒ5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 2008;14:5228-35.
24. Allred DC., Harvey JM., Berardo M., Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
25. Bryan RM., Mercer RJ., Bennett RC., Rennie GC., Lie TH., Morgan FJ. Androgen receptors in breast cancer. Cancer 1984;54: 2436-40.
26. Gonzalez LO., Corte MD., Vazquez J., Junquera S., Sanchez R., Alvarez AC., Rodriguez JC., Lamelas ML., Vizoso FJ. Androgen receptor expresion in breast cancer: relationship with clinico-pathological characteristics of the tumors., prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008;8:149.
27. Peters AA., Buchanan G., Ricciardelli C., Bianco-Miotto T., Cen-tenera MM., Harris JM., Jindal S., Segara D., Jia L., Moore NL., Henshall SM., Birrell SN., Coetzee GA., Sutherland RL., Butler LM., Tilley WD. Androgen receptor inhibits estrogen receptor- alpha activity and is prognostic in breast cancer. Cancer Res 2009;69:6131-40.
28. Bryan RM., Mercer RJ., Bennett RC., Rennie GC. Prognostic factors in breast cancer and the development of a prognostic index. Br J Surg 1986;73:267-71.
29. Castellano I., Allia E., Accortanzo V., Vandone AM., Chiusa L., Arisio R., Durando A., Donadio M., Bussolati G., Coates AS., Viale G., Sapino A. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 2010;124:607-17.
30. Park S., Koo JS., Kim MS., Park HS., Lee JS., Lee JS., Kim SI., Park BW., Lee KS. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 2011;22:1755-62.
31. Rakha EA., El-Sayed ME., Green AR., Lee AH., Robertson JF., Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;10:25-32.
32. Koo JS., Jung W., Jeong J. The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast cancer. Jpn J Clin Oncol 2009;39:560-8.
33. Ogawa Y., Hai E., Matsumoto K., Ikeda K., Tokunaga S., Naga-hara H., Sakurai K., Inoue T., Nishiguchi Y. Androgen receptor expression in breast cancer: relationship with clinicopatholo-gical factors and biomarkers. Int J Clin Oncol 2008;13:431-5.
34. Hu R., Dawood S., Holmes MD., Collins LC., Schnitt SJ., Cole K., Marotti JD., Hankinson SE., Colditz GA., Tamimi RM. Androgen receptor expression and breast cancer survival in postmenopau-sal women. Clin Cancer Res 2011;17:1867-74.
35. Tang D., Xu S., Zhang Q., Zhao W. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer. Med Oncol 2011. DOI: 10.1007/s12032-011-9948-2.
36. He J., Peng R., Yuan Z., Wang S., Peng J., Lin G., Jiang X., Qin T. Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 2011. DOI: 10.1007/s12032-011-9832-0.
37. Micello D., Marando A., Sahnane N., Riva C., Capella C., Sessa F. Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers. Virchows Arch 2010;457: 467-76.
38. Novelli F., Milella M., Melucci E., Di Benedetto A., Sperduti I., Perrone-Donnorso R., Perracchio L., Venturo I., Nistico C., Fabi A., Buglioni S., Natali PG., Mottolese M. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008;10: R74.